摘要
目的:系统评价联合还原型谷胱甘肽治疗乙型病毒性肝炎的有效性。方法:计算机检索PubMed、Medline、Embase、Co-chrane图书馆和CBM、VIP、CNKI数据库,按纳入与排除标准选择随机对照试验(RCT),对纳入研究的方法学质量进行评价,提取资料,用RevMan5.0软件对数据进行Meta分析。结果:总共纳入11篇文献,均存在方法学质量问题,可能存在较高的偏倚风险。Meta分析结果表明:①还原型谷胱甘肽+常规治疗组在改善总有效率[RR=1.23,95%CI(1.13,1.33)]、降低丙氨酸氨基转移酶(ALT)[WMD=22.00,95%C(I0.18,43.82)]方面优于常规组,但在降低天冬氨酸氨基转移酶(AST)以及总胆红素(TBIL)方面,2组比较无统计学差异;②还原型谷胱甘肽+甘草酸二铵+常规治疗组在改善总有效率[RR=1.23,95%CI(1.13,1.33)]、ALT[WMD=30.40,95%CI(23.97,36.84)]、AST[WMD=51.39,95%CI(11.54,91.24)]、TBIL[WMD=13.64,95%CI(11.49,15.44)]方面都优于甘草酸二铵+常规治疗组;③还原型谷胱甘肽+甘草酸苷+常规治疗组在改善总有效率[RR=1.50,95%C(I1.20,1.88)]方面优于甘草酸苷+常规治疗组。结论:联合还原型谷胱甘肽治疗乙型病毒性肝炎有一定的疗效,可提高治疗的总有效率,降低ALT、AST、TBIL水平。
OBJECTIVE： To evaluate the efficacy of reduced glutathione in the treatment of hepatitis B systematically. METHODS： Retrieved from PubMed, Medline, Embasem, Cochrane Library, CBM, VIP, CNKI Databases, randomized controlled trials were collected according to inclusion and exclusion criteria. Methodological quality of included studies was evaluated. Meta-anal- ysis was conducted using RevMan 5.0 software. RESULTS： A total of 11 RCTs were included. The quality of included trials was low. The result of meta-analysis showed that： （1） in reduced glutathione＋routine vs. routine group, the total effective [RR=l.23, 95%CI（1.13,1.33）], ALT [WMD=22.00,95%CI（O.18,43.82）], but there was no significant difference in AST and TBIL. （2） in reduced glutathione ＋ ganlixin ＋ routine vs. ganlixin＋ routine group, the total effective rate [RR= 1.23, 95 % CI （ 1.13, 1.33）], ALT [WMD=30.40,95%CI（23.97,36.84）], AST [WMD=51.39,95%CI（11.54,91.24）], TBIL [WMD= 13.64,95%CI（11.49, 15.44）] were all better than control group. （3） in reduced glutathione＋glycyrrhizin＋routine vs. glycyrrhizin＋routine group, the total effective rate [RR= 1.50,95%CI（1.20, 1.88）] were better than control group. CONCLUSION： Clinical evidence shows that reduced glutathione for hepatitis B has a certain effect, can increase overall response effect, reduce liver enzymes and total bilirubin to improve the cure rate of hepatitis B patients for clinical reference.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第8期734-737,共4页
China Pharmacy
